News | March 16, 2012

Depression Increases Death Risk in Coronary Stent Patients

March 16, 2012 - Depression increases the risk of death in patients who have a coronary stent implanted. After seven years of follow up, depressed patients were 1.5 times more likely to have died than non-depressed patients. The findings were independent of age, gender, clinical characteristics, anxiety and the distressed (Type D) personality.

The research was presented at the 12th Annual Spring Meeting on Cardiovascular Nursing, March 16-17, in Copenhagen, Denmark.

Depression has been associated with poor outcomes in coronary artery disease but previous studies have mainly looked at short-term effects, primarily in patients who have had a myocardial infarction or a coronary bypass operation. The current study (FPN 17) investigated the impact of depression on mortality during a seven-year follow up period in patients treated with percutaneous coronary intervention (PCI).

For the study, 1,234 PCI patients aged 26-90 years (average age 62) from the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry completed the Hospital Anxiety and Depression Scale (HADS) to assess depression six months after having a stent implanted. The endpoint was all-cause mortality.

The prevalence of depression was 26.3 percent (324 out of 1234 patients). After seven years there were 187 deaths in total (15.2 percent). The incidence of all-cause mortality in depressed patients was 23.5 percent (76 out of 324 patients) versus 12.2 percent (111 out of 910 patients) in non-depressed patients.

Depression was independently associated with all-cause mortality (hazard ratio=1.56; 95 percent confidence interval [1.03–2.35], p = .035) after adjusting for sociodemographics (age, gender), clinical characteristics, anxiety and the Type D personality. Clinical characteristics included type of stent (drug eluting/bare metal), number of vessels obstructed, body mass index, past cardiac surgery or myocardial infarction, indication for the PCI procedure, coronary risk factors (hypertension, hypercholesterolemia, diabetes, family history of cardiovascular disease, smoking) and cardiac medications (aspirin, ACE inhibitors, beta blockers, calcium antagonists, diuretics, nitrates and statins).

Male gender, older age, and diabetes mellitus were also significantly associated with an increased risk of death after seven years of follow up, whereas statins were associated with a reduced risk. Anxiety and Type D personality had no significant effect on all-cause mortality.

“The main finding is that patients who are depressed after coronary stenting have a worse prognosis,” says lead author Nikki Damen, a Ph.D. student at Tilburg University in the Netherlands. “They die earlier than non-depressed patients.”

The reasons for the finding are under investigation. One possible explanation is that depressed patients may have less healthy lifestyles with regard to smoking, drinking alcohol, physical activity and diet, and may be less likely to take their medications. Another possible explanation is that depression could alter the activity of the sympathetic nervous system, leading to increases in heart rate and blood pressure.

“Doctors and nurses have traditionally focused on medical factors like diabetes or family history of cardiovascular disease when assessing PCI patients’ risk of death, but that’s not the whole picture,” says Damen. “Psychological factors do matter as well, in combination with the medical factors.”

She adds: “More research is needed to determine how to screen for depression in cardiovascular patients, and then how to provide treatment.”

For more information: www.escardio.org


Related Content

News | Cardiovascular Clinical Studies

May 1, 2024 — A study in more than 3,000 US counties, with 315 million residents, has suggested that air pollution is ...

Home May 01, 2024
Home
News | Cardiovascular Clinical Studies

April 30, 2024 — Regenerative heart therapies involve transplanting cardiac muscle cells into damaged areas of the heart ...

Home April 30, 2024
Home
News | Cardiovascular Clinical Studies

April 24, 2024 —Hello Heart, a digital leader in preventive heart health, today announced results from its latest study ...

Home April 24, 2024
Home
News | Cardiovascular Clinical Studies

April 22, 2024 — Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, welcomes the ...

Home April 22, 2024
Home
News | Cardiovascular Clinical Studies

April 16, 2024 — CVRx, Inc., a commercial-stage medical device company, announced today the availability of additional ...

Home April 16, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 — Transcatheter aortic valve replacement (TAVR) was found to bring no increased risks and was associated ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 — People with a buildup of fatty atherosclerotic plaque in the heart’s arteries considered at risk of ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Patients who took an angiotensin-converting enzyme (ACE) inhibitor while undergoing cancer treatment ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — One of the first studies to attempt to treat early-stage heart failure in patients with Type 2 diabetes ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — The investigational drug ninerafaxstat showed a good tolerability and safety profile, along with ...

Home April 09, 2024
Home
Subscribe Now